One would think from the wording that the FDA granted them a new rolling review. Since the only the substantial problem was the receptor occupancy test, review of all other sections should be perfunctory. The one outstanding question is does "on schedule" mean that the FDA accepted a dose justification without a receptor occupancy test or is "on schedule" still dependent on the FDA's decision on that. Maybe we will find out Wednesday.